Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.80 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.55 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18680037 | 0.99 | TLR7 (0.79) | TLR7TLR8 | |
| SCHEMBL18429392 | 0.90 | TLR7 (0.86) | TLR7TLR8 | |
| Cpg-52852 SCHEMBL483385 | 0.89 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL18680036 | 0.89 | TLR7 (0.85) | TLR7TLR8 | |
| Cpg-52852 SCHEMBL29371102 | 0.89 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL13722028 | 0.87 | TLR7 (0.82) | TLR7TLR8 | |
| SCHEMBL3979207 | 0.87 | TLR7 (0.82) | TLR7TLR8 | |
| SCHEMBL25636046 | 0.86 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL29182347 | 0.86 | TLR7 (0.94) | TLR7TLR8 | |
| SCHEMBL23554228 | 0.85 | TLR7 (0.78) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547761-B1 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210284750-A1 | Immunoconjugate Synthesis Method | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| US-11110178-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200206357-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10675358-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20190015516-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-9556167-B2 | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) | YALE UNIVERSITY (US) | 2017-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206357-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | TLR7 58/4885TLR8 56/4885NUDT1 3204/4885 |
| US-10675358-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | TLR7 58/4885TLR8 56/4885NUDT1 3204/4885 |
| US-20190015516-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | TLR7 121/4885TLR8 99/4885NUDT1 3371/4885 |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | TLR7 57/4885TLR8 59/4885NUDT1 3013/4885 |
| US-20210284750-A1 | Immunoconjugate Synthesis Method | FCGR3B, FCGR1A, FCGR2A | TLR7 84/4885TLR8 435/4885NUDT1 4005/4885 |
| US-11547761-B1 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | TLR7 58/4885TLR8 56/4885NUDT1 3204/4885 |
| US-11110178-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | TLR7 58/4885TLR8 56/4885NUDT1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.